Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF ) Freely available
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (15)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Hughes, E. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hughes, E. G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Human Reproduction, Vol. 18, No. 5, 912-914, May 2003
© 2003 European Society of Human Reproduction and Embryology

Stimulated intra-uterine insemination is not a natural choice for the treatment of unexplained subfertility

‘Effective treatment’ or ‘not a natural choice’?

Edward G. Hughes

Department of Obstetrics & Gynecology, McMaster University Medical Centre, 1200 Main Street West, Room 4D14, Hamilton, ON L8N 3Z5, Canada. E-mail: hughese{at}mcmaster.ca

Helping couples to choose appropriate therapy for their unexplained subfertility demands a review of evidence for treatment benefit and harm, in the context of both patients’ and clinicians’ experience and perspective. Ovulation induction (OI) with clomiphene (CC) or gonadotrophin (FSH) and intrauterine insemination (IUI) are often chosen before resorting to IVF. The appropriateness of starting with these low and intermediate intensity treatments is supported by evidence that CC/IUI increases cycle fecundity two- to three-fold, and FSH/IUI, three- to five-fold over the baseline chance of pregnancy in this patient group. While both OI/IUI and IVF have adverse effects which deserve vigorous attention, particularly multiple pregnancy and ovarian hyperstimulation syndrome (OHSS), the balance between benefits and costs often favours OI/IUI. The cost per live birth and potential for OHSS appears lower with OI/IUI, and the proportion of multiple pregnancies similar to that seen with IVF. For these as well as physical and spiritual reasons, OI/IUI is often a natural starting point for couples, especially when female age and duration of subfertility are favourable.

Key words: clomiphene citrate/gonadotrophin/intrauterine insemination/ovarian hyperstimulation syndrome/unexplained subfertility


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Hum ReprodHome page
P.G. Crosignani, E. Somigliana, and on behalf of the Intrauterine Insemination (IUI) S
Effect of GnRH antagonists in FSH mildly stimulated intrauterine insemination cycles: a multicentre randomized trial
Hum. Reprod., February 1, 2007; 22(2): 500 - 505.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
A. Allegra, A. Marino, F. Coffaro, P. Scaglione, F. Sammartano, G. Rizza, and A. Volpes
GnRH antagonist-induced inhibition of the premature LH surge increases pregnancy rates in IUI-stimulated cycles. A prospective randomized trial
Hum. Reprod., January 1, 2007; 22(1): 101 - 108.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
A. M. Abou-Setta, R. T. Mansour, H. G. Al-Inany, M. A. Aboulghar, A. Kamal, M. A. Aboulghar, and G. I. Serour
Intrauterine insemination catheters for assisted reproduction: a systematic review and meta-analysis
Hum. Reprod., August 1, 2006; 21(8): 1961 - 1967.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
W. Ombelet, G. Martens, P. De Sutter, J. Gerris, E. Bosmans, G. Ruyssinck, P. Defoort, G. Molenberghs, and W. Gyselaers
Perinatal outcome of 12 021 singleton and 3108 twin births after non-IVF-assisted reproduction: a cohort study
Hum. Reprod., April 1, 2006; 21(4): 1025 - 1032.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
C.B. Lambalk, A. Leader, F. Olivennes, M.R. Fluker, A. N. Andersen, J. Ingerslev, Y. Khalaf, C. Avril, J. Belaisch-Allart, R. Roulier, et al.
Treatment with the GnRH antagonist ganirelix prevents premature LH rises and luteinization in stimulated intrauterine insemination: results of a double-blind, placebo-controlled, multicentre trial
Hum. Reprod., March 1, 2006; 21(3): 632 - 639.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
E.C. Haagen, W.L.D.M. Nelen, R.P.M.G. Hermens, D.D.M. Braat, R.P.T.M. Grol, and J.A.M. Kremer
Barriers to physician adherence to a subfertility guideline
Hum. Reprod., December 1, 2005; 20(12): 3301 - 3306.
[Abstract] [Full Text] [PDF]

Home page
 Hum Reprod UpdateHome page
W. Ombelet, P. De Sutter, J. Van der Elst, and G. Martens
Multiple gestation and infertility treatment: registration, reflection and reaction--the Belgian project
Hum. Reprod. Update, January 1, 2005; 11(1): 3 - 14.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.